OCEU/CUPE 1750 Calls on WSIB Leadership to Finalize Fair Deal Before Canada Day
These workers — who process injury claims, support safe return-to-work plans, and ensure critical services for injured Ontarians — have made repeated efforts to reach a resolution. The union's bargaining team remains ready 24/7. What's missing is a mandate from WSIB leadership to get the deal done.
"We want to be back at work serving injured workers and protecting Ontario's compensation system," said Harry Goslin, President of OCEU/CUPE 1750. "But we can't do that without a fair offer—and we can't get one unless decision-makers like the CEO are at the table."
Unlike the employer's bargaining team, which requires direction from senior leadership, the union's team is a fully empowered decision-making body. That imbalance has stalled negotiations and prolonged a strike that has disrupted services and placed added pressure on injured workers and frontline staff alike.
"The WSIB has a choice: keep dragging this out, or pull out all the stops to get a deal done before Canada Day," said Goslin. "Our message is simple — WSIB leadership must come to the table with full authority and finalize a fair deal before Canada Day. Injured workers and the people they serve cannot wait any longer."
OCEU is calling on WSIB's CEO and board of directors to act now and get this done before Canada Day to restore stability, end this disruption, and reach a respectful settlement that reflects the essential work these employees do every day.
mb/cope491
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625824949/en/
Contacts
For more information, please contact:Bill ChalupiakCUPE Communications Representativewchalupiak@cupe.ca 416-707-1401
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Bombardier stock hits highest level since 2011; analysis praises US$1.7B deal
Bombardier's ( stock hit its highest level since 2011 on Wednesday. Analysts are hailing the Canadian business jet maker's recent US$1.7 billion deal with an anonymous buyer as the latest sign of strong demand, and the waning threat of U.S. tariffs. Montreal-based Bombardier announced an order for 50 of its Challenger and Global aircraft, plus a long-term maintenance contract on Monday. Deliveries to the unnamed buyer are set to begin in 2027. The company's Toronto-listed shares have rallied in the weeks since Canada-United States-Mexico Agreement (CUSMA)-compliant goods were exempted from U.S. import tariffs imposed by the White House. Bombardier shares gained as much as 16 per cent on Wednesday, adding 15.14 per cent to $136.60 as at 10:48 a.m. ET. Scotiabank analyst Konark Gupta upgraded the stock to 'sector outperform' from 'sector perform' in a note to clients on Wednesday, while hiking his price target to $150 per share from $105. 'Demand appears to be rebounding with the tariff noise dissipating,' Gupta wrote in a report. 'While our discussion and site visit led us to believe that the company is firing on all cylinders after a lacklustre Q1 order intake, the icing on the cake was its latest significant order win, which boosts our confidence in management's near-term and long-term outlook.' While Bombardier's once-battered stock has gained significant ground, RBC Capital Markets analyst James McGarragle says it remains 'under-appreciated at current levels.' He says the inclusion of a long-term maintenance contract in the deal announced on Monday is good news for investors. 'This deal not only strengthens visibility into future revenue streams, but also solidifies confidence in the company's ability to generate consistent profitability and long-term shareholder value,' McGarragle wrote in a note to clients on Tuesday. He maintains a $108 per share price target on the stock, with an 'outperform' rating. Jeff Lagerquist is a senior reporter at Yahoo Finance Canada. Follow him on X @jefflagerquist. Download the Yahoo Finance app, available for Apple and Android. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
AbbVie Stock At $190: Premium Pricing For A Transformation Story
CANADA - 2025/04/03: In this photo illustration, the AbbVie logo is seen displayed on a smartphone ... More screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period. AbbVie's journey starts with recognizing the scale of its Humira challenge. Once the world's leading pharmaceutical drug (excluding the Covid-19 vaccines), Humira achieved peak sales of $21.2 billion in 2022. However, biosimilar competition has severely impacted its market share, with sales dropping 58% from its peak to $9 billion last year. This decrease signifies a substantial revenue gap that could have incapacitated many companies. Instead of yielding to this pressure, AbbVie has embarked on an aggressive acquisition strategy to enhance its portfolio and broaden its revenue sources. The company's approach has been both methodical and significant, focusing on high-growth therapeutic areas with substantial market potential. For investors seeking lower volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — having outperformed the S&P 500 and delivered returns surpassing 91% since its inception. Additionally, see – SOFI Stock To $30? An Acquisition Spree with Strategic Intent Since the start of 2024, AbbVie has executed an impressive series of acquisitions totaling over $22 billion in deal value. The acquisitions cover various therapeutic areas, showcasing the company's dedication to diversification: This acquisition spree is indicative of more than just opportunistic dealmaking—it signifies a tactical plan to secure leadership positions in high-growth therapeutic sectors while minimizing reliance on any singular asset. AbbVie's history implies this acquisition strategy could yield remarkable returns. The firm's 2016 collaboration with Boehringer Ingelberg serves as an example of this success. For an upfront investment of $595 million, AbbVie obtained global rights to what would become Skyrizi for psoriasis and related indications. That investment has proven immensely profitable, with Skyrizi producing $11.7 billion in sales in 2024. This success story offers a blueprint for how AbbVie's current acquisitions might progress, contingent upon the company's ability to effectively integrate these assets and realize their commercial potential. Even with Humira's declining sales, AbbVie managed to achieve 4% revenue growth last year, showcasing the resilience of its broader portfolio and the preliminary advantages of its acquisition strategy. The company anticipates accelerating revenue growth to high single-digits over the next few years, with even greater earnings growth projected as margins enhance. Valuation Considerations and Market Premium Investors have responded positively to AbbVie's strategic methodology, boosting the stock to approximately $190 per share. At present, the company is trading at 18.5 times its trailing adjusted earnings of $10.27 per share. This valuation signifies a considerable premium relative to AbbVie's historical average of 14x over the past three years and most major pharmaceutical competitors. Bristol Myers Squibb, Merck, and Pfizer are trading at 10 times or less their trailing adjusted earnings, while Johnson & Johnson, Amgen, and Gilead command valuations of 14–15 times. AbbVie's premium valuation illustrates investor faith in its growth strategy and operational capabilities. This elevated multiple seems justified considering the company's robust revenue growth trajectory and ongoing pipeline expansion. As the newly acquired assets contribute to growth and margins improve, the valuation premium may prove to be sustainable or even expand further. However, we could be mistaken in our evaluation. AbbVie's aggressive acquisition strategy has incurred costs to its balance sheet stability. The company currently holds $70 billion in debt against a market capitalization of $336 billion, leading to a debt-to-equity ratio of 21.3%—moderately above the S&P 500 average of 19.4%. More concerning is the company's cash position in relation to its asset base. With only $5.2 billion in cash and equivalents out of $136 billion in total assets, AbbVie's cash-to-assets ratio is alarmingly low at 3.8%. This limited financial flexibility could limit future strategic opportunities or compel the company to rely more extensively on debt financing for future acquisitions. AbbVie's evolution from a Humira-reliant firm to a diversified pharmaceutical powerhouse represents one of the industry's most ambitious strategic shifts. For investors ready to accept balance sheet risks and a premium valuation, the company's execution history and growth potential position it as a possibly attractive long-term investment, even at current levels around $190 per share. On a connected note, are you aware that Merck might confront the same challenges AbbVie did a few years ago with Humira? Explore our insights on – Merck Stock's Ticking Keytruda Time Bomb. Now, there always remains a meaningful risk when investing in a single, or just a handful of stocks. Consider the Trefis High Quality (HQ) Portfolio which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the past 4-year period. Why is that? Collectively, HQ Portfolio stocks delivered superior returns with lower risk compared to the benchmark index; less of a roller-coaster experience, as evidenced in HQ Portfolio performance metrics.
Forbes
an hour ago
- Forbes
UnitedHealth: Buy Or Sell UNH Stock At $325?
CANADA - 2025/04/06: In this photo illustration, the UnitedHealth Group logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) UnitedHealth's stock (NYSE:UNH) has undergone a noticeable decline, decreasing from a peak of around $600 in April to about $275 in May, and then making a slight recovery to $325. This drop followed the company's announcement of disappointing Q1 results, the later retraction of its earnings forecast, and sudden shifts in top management. While these occurrences have naturally raised concerns regarding UNH stock, it is also trading at very appealing valuations. Additionally, as outlined below, the company exhibits robust operating performance and financial health across key metrics such as Growth, Profitability, Financial Stability, and Downturn Resilience. Nevertheless, for those investors who prefer less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — having surpassed the S&P 500 and delivered returns greater than 91% since its inception. Separately, see – SOFI Stock To $30? How Does UnitedHealth's Valuation Look vs. The S&P 500? When considering what you pay per dollar of sales or profit, UNH stock appears inexpensive in relation to the broader market. How Have UnitedHealth's Revenues Grown Over Recent Years? UnitedHealth's Revenues have exhibited significant growth in recent years. How Profitable Is UnitedHealth? UnitedHealth's profit margins are significantly lower than those of most companies covered by Trefis. Does UnitedHealth Look Financially Stable? UnitedHealth's balance sheet appears robust. How Resilient Is UNH Stock During A Downturn? UNH stock has proven to be more resilient than the benchmark S&P 500 index during some recent downturns. As investors speculate on the possibility of a soft landing in the U.S. economy, how serious could it get if another recession strikes? Our dashboard How Low Can Stocks Go During A Market Crash shows how significant stocks fared during and after previous market crashes. Putting All The Pieces Together: What It Means For UNH Stock In conclusion, UnitedHealth's performance regarding the outlined metrics is as follows: UnitedHealth has shown strong performance across the previously mentioned parameters. This, in conjunction with its current low valuation, renders the stock appealing and reinforces our finding that UNH represents a worthwhile buying opportunity. Of course, there's always a level of uncertainty. In light of the recent challenges, including Centene's latest withdrawal of guidance, investors may be cautious about selecting UNH. However, for long-term investors, the presently discounted valuation is likely advantageous, especially given the company's consistent history of strong performance. While UNH stock appears promising, investing in a single stock can carry risks. Conversely, the Trefis High Quality (HQ) Portfolio, comprising 30 stocks, has a history of comfortably outperforming the S&P 500 over the last 4-year period. What accounts for this? Collectively, HQ Portfolio stocks produced superior returns with lower risk compared to the benchmark index; providing a less turbulent experience, as demonstrated by HQ Portfolio performance metrics.
